Find the latest clinical trials by condition, location & phase
Browse and search for drug information and related clinical trials
Explore a comprehensive list of organizations, including their profiles and details.
Latest updates on clinical trials, pharmaceuticals, and healthcare companies
Stay informed with timely notifications on clinical trials and research advancements.
No overview information available.
No background information available.
No indication information available.
No associated conditions information available.
COUR Pharmaceuticals' CNP-104, a novel therapy for primary biliary cholangitis (PBC), has been granted Orphan Drug Designation by the FDA.
ALG-055009, a thyroid hormone receptor beta agonist, demonstrated statistically significant reductions in liver fat in a Phase 2a study for MASH, showing promise for MASH resolution and fibrosis improvement.
CNP-104 demonstrated a statistically significant decrease in liver stiffness compared to placebo in patients with primary biliary cholangitis (PBC).